Skip to main content

Advertisement

SpringerLink
Log in

Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone size

  • Published:
Current Osteoporosis Reports Aims and scope Submit manuscript

Abstract

The treatment of osteoporotic women with recombinant human parathyroid hormone (rhPTH[1-34]) increases bone mineral density and reduces fracture risk. However, there has been concern that the initiation of therapy in women with low bone mass may cause an early and transient increased fracture risk because PTH stimulates bone remodeling, which in its first phase is associated with bone resorption. Animal and human studies suggest, however, that the stimulation of remodeling caused by rhPTH(1–34) does not lead to a deterioration of bone’s mechanical properties or to an increased fracture risk even early in the treatment. There are several reasons for this. Bone biomarkers associated with formation rise earlier than those associated with resorption, suggesting that there is an initial period prior to the stimulation of remodeling during which bone formation occurs on surfaces without prior resorption. This initial period of formation may protect the patient from the later small and transient losses that occur through remodeling. Moreover, the increased remodeling occurs on cancellous surfaces or close to the endosteal surface of bone, where its mechanical effect is minimal. Additionally, these transient losses may be compensated by periosteal apposition that maintains the overall strength of the bone. Thus, the early stimulation of bone formation without prior resorption, and the redistribution of bone from cancellous and endocortical surfaces to the periosteal surface combine to prevent the mechanical deterioration that could otherwise occur with a transient acceleration of bone remodeling in a patient with low bone mass.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Lindsay R, Zhou H, Cosman F, et al.: Short term response to parathyroid hormone (1-34hPTH) in human iliac crest bone using a unique quadruple (double double) tetracycline labeling regimen and single biopsy. J Bone Miner Res 2003, 18:S54.

    Google Scholar 

  2. Arlot M, Roux JP, Portero N, et al.: Comparison of early bone histomorphometric effects of parathormone and alendronate in osteoporotic women. [in French]. Rev Med Suisse Romande 2004, 12:91–92.

    Google Scholar 

  3. Bradbeer JN, Arlot ME, Meunier PJ, Reeve J: Treatment of osteoporosis with parathyroid peptide (hPTH 1–34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone. Clin Endocrinol (Oxf) 1992, 37:282–289.

    CAS  Google Scholar 

  4. Dempster DW, Cosman F, Kurland ES, et al.: Effects of daily treatment with parathyroid hormone on bone micro-architecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001, 16:1846–1853.

    Article  PubMed  CAS  Google Scholar 

  5. Dempster DW, Zhou H, Cosman F, et al.: PTH treatment directly stimulates bone formation in cancellous and cortical bone in humans. J Bone Miner Res 2001, 16:S179.

    Article  Google Scholar 

  6. Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434–1441. Report of a multicenter, randomized placebo-controlled study of 1637 postmenopausal women given 20 or 40 μg of rhPTH(1-34) daily for an average of 19 months. BMD increased significantly in the lumbar spine and femoral neck and vertebral fracture risk was reduced by 65% to 69%.

    Article  PubMed  CAS  Google Scholar 

  7. Jerome CP, Burr DB, Van Bibber T, et al.: Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 2001, 28:150–159.

    Article  PubMed  CAS  Google Scholar 

  8. Burr DB, Hirano T, Turner CH, et al.: Intermittently administered human parathyroid hormone (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 2001, 16:157–165. Ovariectomized cynomolgus monkeys were treated with 1 or 5 μg/kg/day of rhPTH(1-34) for 18 months or for 12 months followed-up by a 6 month withdrawal period. This study showed that the increased cortical porosity in the humerus caused by the PTH-mediated acceleration of bone remodeling occurred primarily near the endosteal surface and did not reduce the bone’s strength or stiffness.

    Article  PubMed  CAS  Google Scholar 

  9. Yoshikawa T, Turner CH, Peacock M, et al.: Geometric structure of the femoral neck measured using dual-energy x-ray absorptiometry. J Bone Miner Res 1994, 9:1053–1064.

    PubMed  CAS  Google Scholar 

  10. Uusi-Rasi K, Beck TJ, Sievanen H, et al.: Associations of hormone replacement therapy with bone structure and physical performance among postmenopausal women. Bone 2003, 32:704–710.

    Article  PubMed  CAS  Google Scholar 

  11. Duncan CS: Mid-femur geometry and biomechanical properties in 15-to-18-yr-old female athletes. Med Sci Sports Exerc 2002, 34:673–681.

    Article  PubMed  Google Scholar 

  12. Sato M, Kulkarni PM, Jerome C, et al.: Bone mineral density under-represents the skeletal efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] in ovariectomized monkeys. Bone 2003, 32:S77.

    Google Scholar 

  13. Turner CH, Burr DB: Basic biomechanical measurements of bone: a tutorial. Bone 1993, 14:595–608.

    Article  PubMed  CAS  Google Scholar 

  14. Turner CH, Burr DB: Experimental techniques for bone mechanics. In Bone Mechanics Handbook. Edited by Cowin SC. Boca Raton: CRC Press; 2001: 7/1–7/35.

    Google Scholar 

  15. Burr DB, Turner CH: Biomechanics of bone. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Edited by Favus M. Washington DC: American Society for Bone and Mineral Research; 2003:58–64.

    Google Scholar 

  16. Hirano T, Burr DB, Cain RL, Hock JM: Changes in geometry and cortical porosity in adult, ovary-intact rabbits after 5 months treatment with LY333334 (hPTH 1–34). Calcif Tissue Int 2000, 66:456–460.

    Article  PubMed  CAS  Google Scholar 

  17. Martin RB, Burr DB: Structure, Function and Adaptation of Cortical Bone. New York: Raven Press; 1989.

    Google Scholar 

  18. Martin RB, Burr DB, Sharkey NL: Skeletal Tissue Mechanics. New York: Springer; 1998.

    Google Scholar 

  19. Hesp R, Hulme P, Williams D, Reeve J: The relationship between femoral bone density and calcium balance in patients with involutional osteoporsis treated with human parathyroid hormone fragment (hPTH1-34). Metab Bone Dis RelatRes 1981, 2:331–332.

    Article  Google Scholar 

  20. Hodsman AB, Steer BM, Fraher LJ, Drost DJ: Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients. Bone Miner 1991, 14:67–83.

    Article  PubMed  CAS  Google Scholar 

  21. Reeve J, Bradbeer JN, Arlot N, et al.: hPTH 1–34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses. Osteoporos Int 1991, 1:162–170.

    Article  PubMed  CAS  Google Scholar 

  22. Slovik DM, Rosenthal DI, Doppelt SH, et al.: Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25 dihydroxyvitamin D. ] Bone Miner Res 1986, 1:377–381.

    Article  CAS  Google Scholar 

  23. Hirano T, Burr DB, Turner CH, et al.: Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res 1999, 14:536–545.

    Article  PubMed  CAS  Google Scholar 

  24. Sato M, Westmore M, Ma YF, et al.: Teriparatide [PTH (1-34) ] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J Bone Miner Res 2004, 19:623–629. The proximal femur of ovariectomized cynomolgus monkeys treated with 1 or 5 μg/kg/day of rhPTH(1-34) for 18 months was significantly stronger than ovariectomized or Sham-operated controls. This was attributed to increased cortical area, width, and cancellous bone volume that compensated for the increase in porosity.

    Article  PubMed  CAS  Google Scholar 

  25. Turner CH, Burr DB, Hock JM, et al.: The effects of PTH (1-34) on bone structure and strength in ovariectomized monkeys. Adv Exp Med Biol 2001, 496:165–79.

    PubMed  CAS  Google Scholar 

  26. Mashiba T, Burr DB, Turner CH, et al.: Intermittently administered human parathyroid hormone (1-34), LY 333334, on bone mass, remodeling and mechanical properties of cortical bone during the first remodeling cycle in rabbits. Bone 2001, 28:538–547. Using a nonovariectomized animal model, this study tested the idea that acceleration of remodeling by PTH in the first remodeling cycle would cause deterioration of mechanical properties and lead to bone fragility. This study showed that although intracortical remodeling increased within the first 70 days of treatment, increased cortical area due to apposition of bone on cortical surfaces increased bone strength.

    Article  PubMed  CAS  Google Scholar 

  27. Kurland ES, Cosman F, McMahon DJ, et al.: Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000, 85:3069–3076.

    Article  PubMed  CAS  Google Scholar 

  28. Lindsay R, Nieves J, Formica C, et al.: Randomized controlled study of effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women on estrogen with osteoporosis. Lancet 1997, 350:550–556.

    Article  PubMed  CAS  Google Scholar 

  29. McClung M, Miller P, Civitelli R, et al.: Differential effects of teriparatide and alendronate on markers of bone remodeling and areal and volumetric bone density in women with osteoporosis. J Bone Miner Res 2003, 18(Suppl):S40.

    Google Scholar 

  30. Ettinger B, San Martin J, Crans GG, Pavo I: Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004, 19:745–751. Teriparatide (20 μg/day) was administered for 18 months to 59 postmenopausal women who previously had been treated with raloxifene or alendronate. Prior treatment with raloxifene did not blunt the expected increased in BMD caused by terparatide treatment, but prior treatment with alendronate prevented increased BMD for the first 6 months.

    Article  PubMed  CAS  Google Scholar 

  31. Black DM, Greenspan SL, Ensrud KE, et al.: The effects of parathyroid hormone alone or in combination in post-menopausal osteoporosis. N Engl J Med 2003, 349:1207–1215. Two hundred thirty-eight postmenopausal women were given PTH (1-84, 100 μg/day), alendronate (10 mg/day), or both for 12 months. Bone formation increased significantly in the PTH(1-84) group but not in the combination therapy group. The use of alendronate and PTH(1-84) in combination reduced the anabolic effects of PTH, but spine BMD increased the same amount in all groups.

    Article  PubMed  CAS  Google Scholar 

  32. Shergy W, Greenwald M, Woodson G, et al.: Early effect of teriparatide in postmenopausal women with osteoporosis. American Association of Clinical Endocrinologists, 2004.

  33. Marcus R, Wang O, Satterwhite J, Mitlak B: The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003, 18:18–23. In the same cohort of patients used for the Neer et al. [6] study, this study showed teriparatide reduced vertebral fracture risk more in postmenopausal women with very low (T score < -3.3) or moderately low (T score <−2–3.3) bone mass than in those with greater bone mass. The study demonstrates that the initiation of PTH treatment does not increase the early risk for fracture in women with very low bone mass.

    Article  PubMed  CAS  Google Scholar 

  34. Hodsman AB, Kisiel M, Adachi JD, et al.: Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclic hPTH (1-34) therapy in women with severe osteoporosis. Bone 2000, 27:311–318.

    Article  PubMed  CAS  Google Scholar 

  35. Hodsman AB, Hanley DA, Ettinger MP, et al.: Efficacy and safety of human parathyroid hormone (1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003, 88:5212–5220. Treatment of postmenopausal women with 50, 75, or 100 μg PTH (1-84) for 12 months was associated with a significant increase in spine BMD by 3 months. There was a nonsignificant decrease in total hip BMD after 6 months at the highest dose, but a significant increase after the first year.

    Article  PubMed  CAS  Google Scholar 

  36. Finkelstein JS, Hayes A, Hunzelman JL, et al.: The effects of parathyroid hormone, alednronate, or both in men with osteoporosis. N Engl J Med 2003, 349:1215–1226. Eighty-three men with low bone density were given alendronate (10 mg/day for 30 months), PTH (1-34, 40 μg/day for 24 months), or both (for 24 months). BMD at the lumbar spine and femoral neck increased significantly more in men treated with PTH alone than in the combination group. The authors conclude that alendronate attenuates the positive effect of PTH on BMD perhaps by blunting the stimulation of bone formation.

    Google Scholar 

  37. Zanchetta JR, Bogado CE, Ferretti JL, et al.: Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003, 18:539–43. One hundred one postmenopausal women were treated daily with teriparatide at 20 or 40 μg, or with placebo for a median of 18 months. Cortical area, periosteal circumference and crosssectional moments of inertia of the nondominant radius measured by pQCT were significantly greater in the PTH-treated groups compared with placebo-treated controls. This suggests that structure and strength of cortical bone is increased without any detrimental effects on BMD or mineral content.

    Article  PubMed  CAS  Google Scholar 

  38. Uusi-Rasi K, Beck TJ, Oreskovic TL, et al.: Teriparatide [rhPTH(1-34)] improves the structural geometry of the hip. J Bone Miner Res 2002, 17:S208.

    Article  Google Scholar 

  39. Hyldstrup L, Jorgensen JT, Gaich G, et al.: Assessment of effects of LY 333334 (recombinant human parathyroid hormone (1-34) on cortical bone using digital x-ray radiogrammetry. Bone 2001, 28:S97.

    Google Scholar 

  40. Cosman F, Nieves J, Woelfert L, et al.: Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001, 16:925–931.

    Article  PubMed  CAS  Google Scholar 

  41. Deal C, Omizo M, Schwartz EN, et al.: Raloxifene in combination with teriparatide reduces teriparatide-induced stimulation of bone resorption but not formation in postmenopausal women with osteoporosis. J Bone Miner Res 2004, 19:S44.

    Google Scholar 

  42. Lindsay R, Scheele WH, Clancy AD, et al.: Reduction in nonvertebral fragility fractures and increase in spinal bone density is maintained 31 months after discontinuation of recombinant human parathyroid hormone (1-34) in postmenopausal women with osteoporosis. Paper presented at the 2002 Endocrine Society Meeting, San Francisco, CA.

  43. Delmas PD, Licata AA, Crans GG, et al.: Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. J Bone Miner Res 2004, 19:S44.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anatomy and Cell Biology, MS 5035, Indiana University School of Medicine, 635 Barnhill Dr., 46202, Indianapolis, IN, USA

    David B. Burr PhD

Authors
  1. David B. Burr PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Burr, D.B. Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone size. Curr Osteoporos Rep 3, 19–24 (2005). https://doi.org/10.1007/s11914-005-0023-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11914-005-0023-9

Keywords

Search

Navigation